Recombinant Anti-ErbB2 / HER2 antibody [SP101] (ab231438)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [SP101] to ErbB2 / HER2
- Suitable for: mIHC, IHC-P, WB
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-ErbB2 / HER2 antibody [SP101]
See all ErbB2 / HER2 primary antibodies -
Description
Rabbit monoclonal [SP101] to ErbB2 / HER2 -
Host species
Rabbit -
Tested applications
Suitable for: mIHC, IHC-P, WBmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat, Hamster, Dog -
Immunogen
Recombinant fragment within Human ErbB2/ HER2 aa 500-650. The exact sequence is proprietary. Extracellular domain.
Database link: P04626 -
Positive control
- IHC-P: Human breast carcinoma tissue. WB: SK-BR-3 whole cell lysate. mIHC: Human triple-positive breast carcinoma
-
General notes
This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.
Properties
-
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.60
Preservative: 0.1% Sodium azide
Constituents: PBS, 1% BSA -
Concentration information loading...
-
Purity
Protein A/G purified -
Purification notes
Purified from TCS by Protein A/G. -
Clonality
Monoclonal -
Clone number
SP101 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab231438 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
mIHC |
1/100.
|
|
IHC-P |
1/100.
Boil tissue section in citrate buffer, pH 6.0 for 10 minutes followed by cooling at room temperature for 20 minutes. Incubate with primary antibody for 10 minutes at room temperature |
|
WB |
Use a concentration of 0.638 µg/ml. Predicted molecular weight: 137 kDa.
|
Notes |
---|
mIHC
1/100. |
IHC-P
1/100. Boil tissue section in citrate buffer, pH 6.0 for 10 minutes followed by cooling at room temperature for 20 minutes. Incubate with primary antibody for 10 minutes at room temperature |
WB
Use a concentration of 0.638 µg/ml. Predicted molecular weight: 137 kDa. |
Target
-
Function
Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.
In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth. -
Tissue specificity
Expressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth. -
Involvement in disease
Hereditary diffuse gastric cancer
Glioma
Ovarian cancer
Lung cancer
Gastric cancer
Chromosomal aberrations involving ERBB2 may be a cause gastric cancer. Deletions within 17q12 region producing fusion transcripts with CDK12, leading to CDK12-ERBB2 fusion leading to truncated CDK12 protein not in-frame with ERBB2. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.
Contains 1 protein kinase domain. -
Post-translational
modificationsAutophosphorylated. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit (Probable). Ligand-binding increases phosphorylation on tyrosine residues (PubMed:27134172). Signaling via SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007). Dephosphorylated by PTPN12 (PubMed:27134172). -
Cellular localization
Cytoplasm. Nucleus and Cell membrane. Cytoplasm, perinuclear region. Nucleus. Translocation to the nucleus requires endocytosis, probably endosomal sorting and is mediated by importin beta-1/KPNB1. - Information by UniProt
-
Database links
- Entrez Gene: 403883 Dog
- Entrez Gene: 2064 Human
- Entrez Gene: 13866 Mouse
- Entrez Gene: 24337 Rat
- Omim: 164870 Human
- SwissProt: O18735 Dog
- SwissProt: P04626 Human
- SwissProt: P70424 Mouse
see all -
Alternative names
- Verb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog antibody
- C erb B2/neu protein antibody
- CD340 antibody
see all
Images
-
Multiplex immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human triple-positive breast carcinoma tissue sections labeling ErbB2 / HER2 with ab231438 at 1/100 dilution (1.59 µg/ml). Heat mediated antigen retrieval with Citrate buffer (pH 6.0, epitope retrieval solution 1) for 20 mins and Opal Polymer HRP Ms + Rb was used as the secondary antibody. DAPI was used as the nuclear counterstain.
Panel A: merged staining of anti-Progesterone Receptor (PR) (magenta; Opal™690), anti-HER2 (red; Opal™570) and anti-Estrogen Receptor (ER) (green; Opal™520) on human triple-positive breast carcinoma.
Panel B: anti-PR stained on nucleus of cancer cells.
Panel C: anti-HER2 stained on membrane of cancer cells.
Panel D: anti-ER stained on nucleus of cancer cells.
The section was incubated in three rounds of staining: in the order of ab16661 for 30 mins, then ab16660 and ab231438 for 10 mins at room temperature. Each round was followed by a separate fluorescent tyramide signal amplification system.
The immunostaining was performed on a Leica Biosystems BOND® RX instrument with an Opal™ 4-color kit. Image acquisition was performed with Leica SP8 confocal microscope. -
Lane 1 : Anti-ErbB2 / HER2 antibody [SP101] (ab231438) at 0.638 µg/ml (purified)
Lane 2 : Anti-GAPDH antibody [EPR16891] - Loading Control (ab181602)
All lanes : SK-BR-3 (Human breast adenocarcinoma epithelial cell) whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 0.05 µg/ml
Predicted band size: 137 kDa
Observed band size: 180 kDa why is the actual band size different from the predicted?Blocking/Diluting Buffer and concentration: 5% NFDM /TBST
-
Multiplex immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human mammary gland tissue sections labeling ErbB2 / HER2 with ab231438 at 1/100 dilution (1.59 µg/ml). Heat mediated antigen retrieval with Citrate buffer (pH 6.0, epitope retrieval solution 1) for 20 mins and Opal Polymer HRP Ms + Rb was used as the secondary antibody. DAPI was used as the nuclear counterstain.
Panel A: merged staining of anti-Progesterone Receptor (PR) (magenta; Opal™690), anti-HER2 (red; Opal™570) and anti-Estrogen Receptor (ER) (green; Opal™520) on human mammary gland.
Panel B: anti-PR stained on nucleus of some ductal cells.
Panel C: anti-HER2 stained on no cells.
Panel D: anti-ER stained on nucleus of some ductal cells.
The section was incubated in three rounds of staining: in the order of ab16661 for 30 mins, then ab16660 and ab231438 for 10 mins at room temperature. Each round was followed by a separate fluorescent tyramide signal amplification system.
The immunostaining was performed on a Leica Biosystems BOND® RX instrument with an Opal™ 4-color kit. Image acquisition was performed with Leica SP8 confocal microscope. -
Panel A: merged staining of anti-Progesterone Receptor (PR) (magenta; Opal™690), anti-HER2 (red; Opal™570) and anti-Estrogen Receptor (ER) (green; Opal™520) on human triple-negative breast carcinoma.
Panel B: anti-PR stained on no cells.
Panel C: anti-HER2 stained on no cells.
Panel D: anti-ER stained on no cells.
The section was incubated in three rounds of staining: in the order of ab16661 for 30 mins, then ab16660 and ab231438 for 10 mins at room temperature. Each round was followed by a separate fluorescent tyramide signal amplification system.
The immunostaining was performed on a Leica Biosystems BOND® RX instrument with an Opal™ 4-color kit. Image acquisition was performed with Leica SP8 confocal microscope. -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ErbB2 / HER2 antibody [SP101] (ab231438)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human breast carcinoma tissue sections labeling ErbB2 / HER2 with ab231438 at 1/100 dilution (6.38 µg/ml). Heat mediated antigen retrieval with Bond™ Epitope Retrieval Solution 1 (pH 6.0) for 10mins Goat Anti-Rabbit & Mouse IgG (HRP) was used as the secondary antibody. Hematoxylin was used as a counterstain. Membranous staining on the human breast carcinoma, performed on a Leica Biosystems BOND™ RX instrument.
The section was incubated with ab231438 for 30 mins at room temperature. -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ErbB2 / HER2 antibody [SP101] (ab231438)
Formalin-fixed, paraffin-embedded human breast carcinoma tissue stained for ErbB2 / HER2 using ab231438 at 1/100 dilution in immunohistochemical analysis.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (0)
ab231438 has not yet been referenced specifically in any publications.